About Bio-Reference Laboratories (NASDAQ = BRLI), Inc. and GeneDxBRLI is the fourth largest full service laboratory in the United States, primarily a clinical testing laboratory servicing physician offices with concentrations in the focused markets of esoteric testing, molecular diagnostics, anatomical pathology, women's health and correctional health care. BRLI is a national oncology laboratory operating as GenPath. Better science, superior technology and better service have enabled GenPath to earn a reputation as one of the premier hematopathology laboratories in the country. BRLI's innovative technology platform for sexually transmitted infections has enabled it to expand as a national laboratory in the area of Women's Health. GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and is typically recognized as the leading laboratory for testing of rare genetic diseases; GeneDx has now become a technology leader with XomeDx, whole exome sequencing test, and its Next-Gen sequence offerings that are currently offered in several disease areas, such as cardiology, neurology, immunology, ophthalmology and prenatal areas.SOURCE Bio-Reference Laboratories, Inc.